-
1
-
-
0003520592
-
Statistics on blindness in the model reporting area 1969-1970
-
Publ no 73-427. Washington: Us Government Printing Office;
-
Kahn HA, Moorehead HB. Statistics on blindness in the model reporting area 1969-1970. United States Department of Healt, Education and Welfare. Publ no 73-427. Washington: Us Government Printing Office; 1973.
-
(1973)
United States Department of Healt, Education and Welfare
-
-
Kahn, H.A.1
Moorehead, H.B.2
-
2
-
-
0020561796
-
-
rd. Senile macular degeneration: a review of epidemiologic features. Am J Epidemiol, 1983;118:132-51.
-
rd. Senile macular degeneration: a review of epidemiologic features. Am J Epidemiol, 1983;118:132-51.
-
-
-
-
3
-
-
0023231173
-
The dimensions of the problem of eye disease among the elderly
-
Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology, 1987;94:1191-5.
-
(1987)
Ophthalmology
, vol.94
, pp. 1191-1195
-
-
Pizzarello, L.D.1
-
4
-
-
26844538065
-
Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials
-
Macular Photocoagulation study Group
-
Macular Photocoagulation study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol, 1993;107:1374-80.
-
(1993)
Arch Ophthalmol
, vol.107
, pp. 1374-1380
-
-
-
5
-
-
26844536148
-
The burden of age-related macular degeneration. A value-based analysis
-
Forthcoming
-
Brown GC, Brown MM, Sharma S, Roth Z, Campanella J, Beauchamp G. The burden of age-related macular degeneration. A value-based analysis. Curr Opin Ophthalmol, Forthcoming.
-
Curr Opin Ophthalmol
-
-
Brown, G.C.1
Brown, M.M.2
Sharma, S.3
Roth, Z.4
Campanella, J.5
Beauchamp, G.6
-
6
-
-
0037230255
-
Quality of life with macular degeneration. Perceptions of patients, clinicians and community members
-
Stein JD, Brown MM, Brown GC, Sharma S, Hollands H. Quality of life with macular degeneration. Perceptions of patients, clinicians and community members. Brit J Ophthalmol, 2003;87:8-12.
-
(2003)
Brit J Ophthalmol
, vol.87
, pp. 8-12
-
-
Stein, J.D.1
Brown, M.M.2
Brown, G.C.3
Sharma, S.4
Hollands, H.5
-
7
-
-
0342632445
-
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One year results of 2 randomized clinical trials - TAP
-
Treatment of age-related macular degeneration with photodynamic therapy study group
-
Treatment of age-related macular degeneration with photodynamic therapy study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol, 1999;117:1329-45.
-
(1999)
Arch Ophthalmol
, vol.117
, pp. 1329-1345
-
-
-
8
-
-
0035009086
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy
-
Verteporfin in Photodynamic Therapy Study Group
-
Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
-
(2001)
Am J Ophthalmol
, vol.131
, pp. 541-560
-
-
-
9
-
-
16844375997
-
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: Two year results of a randomized clinical trial
-
Visudyne in Minimally Classic CNV (VIM) Study Group
-
Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: two year results of a randomized clinical trial. Arch Ophthalmol, 2005;123:448-5.
-
(2005)
Arch Ophthalmol
, vol.123
, pp. 448-445
-
-
-
10
-
-
33748883015
-
Fréquence des récidives après thérapie photodynamique à la Verteporfine dans la dégénérescence maculaire liée à l'âge
-
Donati G. Fréquence des récidives après thérapie photodynamique à la Verteporfine dans la dégénérescence maculaire liée à l'âge. J Fr Ophtalmol, 2006;29:803-7.
-
(2006)
J Fr Ophtalmol
, vol.29
, pp. 803-807
-
-
Donati, G.1
-
11
-
-
0035555466
-
Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with Verteporfin therapy
-
Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with Verteporfin therapy. Seminars in Ophthalmol, 2001;16:218-22.
-
(2001)
Seminars in Ophthalmol
, vol.16
, pp. 218-222
-
-
Greiner, R.A.1
-
12
-
-
26844485888
-
The Cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data
-
Brown GC, Brown MM, Campanella J, Beauchamp JR. The Cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data. Am J Ophthalmol, 2005;140:679-87.
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 679-687
-
-
Brown, G.C.1
Brown, M.M.2
Campanella, J.3
Beauchamp, J.R.4
-
13
-
-
0026575912
-
How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
-
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J, 1992;146:473-81.
-
(1992)
Can Med Assoc J
, vol.146
, pp. 473-481
-
-
Laupacis, A.1
Feeny, D.2
Detsky, A.S.3
Tugwell, P.X.4
-
14
-
-
85031434075
-
Five-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 7
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Five-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 7. Arch Ophthalmol, 2005;123:1283-5.
-
(2005)
Arch Ophthalmol
, vol.123
, pp. 1283-1285
-
-
-
15
-
-
0036822175
-
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: Three year results of an open-label extension of 2 randomised clinical trials - TAP
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group
-
Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: three year results of an open-label extension of 2 randomised clinical trials - TAP report no 5. Arch Ophthalmol, 2002;120:1307-14.
-
(2002)
Arch Ophthalmol
, vol.120
, pp. 1307-1314
-
-
-
17
-
-
0242550060
-
Cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK. abstract no. PES6
-
Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy (PDT) with verteporfin in the UK. abstract no. PES6. Value Health, 2002;5:247.
-
(2002)
Value Health
, vol.5
, pp. 247
-
-
Smith, D.H.1
Fenn, P.2
Drummond, M.3
-
18
-
-
0034759058
-
The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration
-
Sharma S, Brown GC, Brown MB, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology, 2001;108:2051-9.
-
(2001)
Ophthalmology
, vol.108
, pp. 2051-2059
-
-
Sharma, S.1
Brown, G.C.2
Brown, M.B.3
Hollands, H.4
Shah, G.K.5
-
20
-
-
0242466582
-
Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: The case of Australia [abstract no. PES6]
-
Lees M, Davey P, Price N, Aldridge G, Mudge M, Stokes J. Economic evaluation of photodynamic therapy with verteporfin for small subfoveal CNV lesions: the case of Australia [abstract no. PES6]. Value Health, 2003;110:239.
-
(2003)
Value Health
, vol.110
, pp. 239
-
-
Lees, M.1
Davey, P.2
Price, N.3
Aldridge, G.4
Mudge, M.5
Stokes, J.6
-
21
-
-
4344583798
-
Cost effectiveness of photodynamic therapy with verteporfin for age reated macular degeneration: The UK case
-
Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age reated macular degeneration: the UK case. Br J Ophthalmol, 2004;88:1107-1112.
-
(2004)
Br J Ophthalmol
, vol.88
, pp. 1107-1112
-
-
Smith, D.H.1
Fenn, P.2
Drummond, M.3
-
22
-
-
0035009086
-
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy
-
Verteporfin in Photodynamic Therapy Study Group
-
Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol, 2001;131:541-60.
-
(2001)
Am J Ophthalmol
, vol.131
, pp. 541-560
-
-
-
23
-
-
0034098636
-
What is heartburn worth? A cost-utility analysis of management strategies
-
Heudebert GR, Centor RM, Klapow JC, Marks R, Johnson L, Wilcox CM. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med, 2000;15:175-82.
-
(2000)
J Gen Intern Med
, vol.15
, pp. 175-182
-
-
Heudebert, G.R.1
Centor, R.M.2
Klapow, J.C.3
Marks, R.4
Johnson, L.5
Wilcox, C.M.6
-
24
-
-
0031546091
-
-
Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neurorad, 1997;18:1453-62.
-
Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am J Neurorad, 1997;18:1453-62.
-
-
-
-
25
-
-
4444250849
-
-
Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'beyond the TAP study. Eye, 2004;18:809-13.
-
Barnes RM, Gee L, Taylor S, Briggs MC, Harding SP. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation - 'beyond the TAP study. Eye, 2004;18:809-13.
-
-
-
-
26
-
-
11244296210
-
Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration
-
Frennesson CI, Nilsson SE. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration. Acta Ophthalmol Scand, 2004;82:645-50.
-
(2004)
Acta Ophthalmol Scand
, vol.82
, pp. 645-650
-
-
Frennesson, C.I.1
Nilsson, S.E.2
-
27
-
-
25444443406
-
Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration
-
Shyong MP, Lee FL, Chen SJ, Tung TH, Tsai Dc, Hsu WM. Photodynamic therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. J Chin Med Assoc, 2005;68:419-24.
-
(2005)
J Chin Med Assoc
, vol.68
, pp. 419-424
-
-
Shyong, M.P.1
Lee, F.L.2
Chen, S.J.3
Tung, T.H.4
Tsai, D.5
Hsu, W.M.6
-
28
-
-
26844485888
-
The costutility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data
-
Brown GC, Brown MM, Campanella J, Beauchamp GR. The costutility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data. Am J Ophthalmol, 2005;140:679-87.
-
(2005)
Am J Ophthalmol
, vol.140
, pp. 679-687
-
-
Brown, G.C.1
Brown, M.M.2
Campanella, J.3
Beauchamp, G.R.4
-
29
-
-
33749445317
-
Ranibizumab for Neovascular Age-Related Macular Degeneration
-
for the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) Study Group
-
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY for the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med, 2006;355:1419-31.
-
(2006)
N Engl J Med
, vol.355
, pp. 1419-1431
-
-
Rosenfeld, P.J.1
Brown, D.M.2
Heier, J.S.3
Boyer, D.S.4
Kaiser, P.K.5
Chung, C.Y.6
Kim, R.Y.7
-
30
-
-
33749451356
-
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
-
for the treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Study Group
-
Brown DM, Kaiser PK, Michels M, Soubrane GS, Heier JS, Kim RY, Sy JP, Schneider S for the treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Study Group. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N Engl J Med, 2006;355:1432-44.
-
(2006)
N Engl J Med
, vol.355
, pp. 1432-1444
-
-
Brown, D.M.1
Kaiser, P.K.2
Michels, M.3
Soubrane, G.S.4
Heier, J.S.5
Kim, R.Y.6
Sy, J.P.7
Schneider, S.8
|